Respiri’s wheezo logo scores prime position on Carlton AFLW uniforms
作为卡尔顿足球俱乐部的主要合作伙伴，Respiri的标识将出现在俱乐部的女队制服上。
Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has revealed its product logo will adorn the club’s official women’s uniform and training gear next season.
Carlton unveiled the new design today, which shows the logo for Respiri’s wheezo asthma management device on guernseys to be worn by the AFLW team from 2021.
Carlton chief executive officer Cain Liddle welcomed wheezo as a co-major partner and acknowledged Respiri’s efforts to improve the public’s health.
“Respiri is genuine about its commitment to having a positive impact on the community, which is a philosophy that perfectly aligns with our AFLW program,” he said.
“To have [them] commit to joining us as a co-major partner is testament to the high regard in which our AFLW side is held on and off the field.”
Decision to partner
Meanwhile, Respiri chief executive officer Marjan Mikel explained the company’s decision to partner with Carlton’s women’s team, which has over 4.1 million fans nationwide.
“Our commitment to the health of Australians has never been stronger with the recent launch of our wheezo device,” he said.
“We believe this sponsorship with the Blues will support our mission to improve asthma management by providing patients with a unique medical technology device [that they can use] in the everyday world we live in.”
Management solution
Respiri’s wheezo is an innovative, easy-to-use solution to assist patients – especially children and adolescents – with the management of their asthma.
The handheld device helps the user better understand their condition by compiling crucial and personalised information about their triggers, symptoms, medication usage and other events.
It also provides quick and easy access to the user’s asthma action plan.
In conjunction with an eHealth app, wheezo analyses breath sounds for the presence of wheeze (a typical symptom of asthma) and can enhance asthma management by eliminating guesswork and improving patient understanding.
Earlier this month, Respiri disclosed that an “accelerated design and manufacturing efficiencies” of the wheezo device could result in improved cost savings for the company.
The company said gross margins for its version 3.0 wheezo device and technology will be about 30% lower than previously forecast for 2021.